News & Updates

Adding clarithromycin to standard of care appears to improve clinical response and reduce inflammation in patients with community-acquired pneumonia, as reported in the phase III ACCESS trial.

The addition of sotorasib to panitumumab significantly improves progression-free survival (PFS) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (CRC) compared with the investigator’s choice of standard-of-care (SoC) treatment, according to the CodeBreaK 300 trial presented at ESMO Asia 2023.

Treatment with tiotropium appears to reduce the risk of clinically important deterioration (CID) in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), including those with fewer respiratory symptoms, according to a study.

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

It is safe to use long-term growth hormone (GH) therapy in patients with decompensated cirrhosis (DC), suggests a study, noting improvements in malnutrition and even quality of life (QoL). However, 12-month survival does not seem to improve.

More and more patients in the US are being initiated on immunotherapy within 1 month of death, reflecting the rise in use of immunotherapy overall, according to a study.